Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice
about
Challenges of advanced hepatocellular carcinomaThe Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma.Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System.Historical Comparison of Overall Survival after Hepatic Resection for Patients With Large and/or Multinodular Hepatocellular Carcinoma.How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma.Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort studySurvival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation.The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015): Evidence and Consensus on HCC Management.Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma.Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation.Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC.
P2860
Q28076867-70326F32-563C-463E-8C97-BFEC7C24931CQ35888783-1740B902-91AC-46A7-91F3-800366582D2DQ36106903-0B327996-FEDF-4641-A515-A94716FFCC1EQ36153539-9EFEF230-184C-49C3-9CE9-5BA7135698A6Q36194426-F19E9EC6-A93A-47FE-96EF-4BFD7801603DQ37513083-10D2F7AF-C7FF-4DAD-884C-21256E37EEA0Q37665692-2E56214F-7275-4388-885C-3903EA2546C7Q38708569-8F9E439A-E2C4-44EB-B10A-C3F76E287882Q46027563-610A5B49-8A68-4761-9FA8-B19360B0337EQ47132493-AA0E3AD2-15DF-4B36-9EEB-3E03A364CF68Q47818290-E5E63166-947B-427C-951E-5575C5AC4BFFQ48105164-FB061928-033E-4219-8C84-BBBB701902EBQ50169188-D93E7FAC-5240-4035-A4AB-3EF7BA5D96ABQ52604161-44D75EDF-5D68-4959-AF61-B8C9B117A9B7Q53103129-F271BD85-E69C-42AB-83C5-4ECF87FB6C07
P2860
Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Determinants of survival after ...... rcinoma in real-world practice
@ast
Determinants of survival after ...... rcinoma in real-world practice
@en
type
label
Determinants of survival after ...... rcinoma in real-world practice
@ast
Determinants of survival after ...... rcinoma in real-world practice
@en
prefLabel
Determinants of survival after ...... rcinoma in real-world practice
@ast
Determinants of survival after ...... rcinoma in real-world practice
@en
P2093
P2860
P1433
P1476
Determinants of survival after ...... rcinoma in real-world practice
@en
P2093
Chung-Pin Li
Fa-Yauh Lee
Han-Chieh Lin
I-Cheng Lee
Teh-Ia Huo
Yi-Tzen Chen
P2860
P356
10.1097/MD.0000000000000688
P407
P577
2015-04-01T00:00:00Z